Terry Connolly, K36 Therapeutics CEO

At­las, F-Prime launch K36 Ther­a­peu­tics to ad­vance on­col­o­gy mol­e­cule for elu­sive epi­ge­net­ic tar­get

Af­ter be­ing in stealth for near­ly 11 months, a new biotech has made it­self known, com­plete with an in­flux of cash from some big-name in­vestors.

K36 Ther­a­peu­tics, an on­col­o­gy biotech out of Cam­bridge, MA, emerged from stealth this morn­ing — an­nounc­ing a long-fin­ished $30M Se­ries A co-led by F-Prime Cap­i­tal, At­las Ven­ture and glob­al in­vest­ment firm Eight Roads Ven­tures.

K36 CEO Ter­ry Con­nol­ly told End­points News that the se­ries was ac­tu­al­ly closed back in Feb­ru­ary — and is now just be­ing an­nounced. Con­nol­ly said that he ex­pects the fund­ing to get K36 through proof-of-con­cept stud­ies and hope­ful­ly push the can­di­date to the IND phase, which the biotech plans to file by the end of June next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.